In the era of precision therapy, selective RET‐TKIs, including selpercatinib and pralsetinib, significantly improved the prognosis of advanced RET‐rearranged NSCLC as demonstrated in the LIBRETTO‐001 and ARROW studies.22, 23. This evidence concerns the gene RET and non-small cell lung carcinoma.